BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19941044)

  • 21. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
    Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
    Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
    Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
    Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
    Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
    Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
    Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
    Moon HW; Noh J; Yun YM; Kim HY; Yun IJ; Song J; Kim JQ
    Ann Clin Lab Sci; 2011; 41(3):229-35. PubMed ID: 22075505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
    Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VKORC1 and CYP2C9 genotype distribution in Asian countries.
    Gaikwad T; Ghosh K; Shetty S
    Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.